- The FDA has rescheduled a joint meeting of the Nonprescription Drugs Advisory Committee (NDAC) and the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee (ORUDAC) for May 9 & 10, 2023 to review Perrigo Company plc‘s (NYSE:PRGO) Opill daily oral contraceptive for over-the-counter (OTC) use.
- Perrigo announced in July 2022 that its HRA Pharma affiliate filed an application with the FDA for the Rx-to-OTC switch of Opill, a progestin-only daily birth control pill (also called a mini pill or non-estrogen pill).
- If approved, Opill would be the first ever daily birth control pill available OTC, without a prescription, in the U.S.
- Over-the-counter birth control has support from major medical organizations.
- Perrigo had previously expected approval in the first half of 2023, but the original FDA action date was never disclosed.
- Price Action: PRGO shares are up 1.29% at $34.63 on the last check Tuesday.
Venator Announced Comprehensive Agreement to Enter Prepackaged Chapter 11
Venator Materials PLC ("Venator" or the "Company") (NYSE:VNTR), a global manufacturer and marketer of chemical products, announces that it has reached an agreement with the overwhelming majority of
